Abecma the multiple myeloma treatment Bluebird developed and licensed to Bristol Myers Squibb was supposed to provide a revenue cushion for 2Seventy and help fund its other drug research. But Bristol Myers has had trouble manufacturing supplies and is dealing with strong competition from a rival therapy sold by Johnson  Johnson 